Eledon Pharmaceuticals, Inc. ((ELDN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eledon Pharmaceuticals, Inc. is conducting a clinical study titled AT-1501-K209: BESTOW-EXTENSION, aimed at evaluating the long-term safety and efficacy of Tegoprubart (AT-1501) in kidney transplant recipients. The study’s primary objective is to compare Tegoprubart with Tacrolimus, focusing on the preservation of allograft function, which is crucial for improving transplant outcomes.
The intervention involves two treatments: Tegoprubart, administered intravenously every three weeks, and Tacrolimus, taken orally twice daily. Both are combined with other standard medications to support kidney transplant patients.
This Phase 2 study is non-randomized with a parallel intervention model and no masking, primarily focusing on treatment. Participants continue their regimen from a prior study, ensuring continuity in evaluating long-term effects.
The study began on October 25, 2023, with the last update submitted on July 21, 2025. These dates are significant as they mark the study’s progression and data collection milestones, which are crucial for regulatory and investor timelines.
For investors, the study’s progress may influence Eledon Pharmaceuticals’ stock performance, especially if Tegoprubart shows favorable outcomes compared to existing treatments like Tacrolimus. This could enhance investor sentiment and position Eledon competitively within the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.